Gossamer Bio Inc (GOSS)

$3.11 -0.03 (-0.96%)
Market Cap 705.94M
Revenue (ttm) 114.70M
Net Income (ttm) -56.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -49.29%
Debt to Equity Ratio 0.00
Volume 2,952,100
Avg Vol 3,493,582
Day's Range N/A - N/A
Shares Out 231.46M
Stochastic %K 94%
Beta 1.85
Analysts Strong Sell
Price Target $9.50

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 684 1300
Address:
3115 Merryfield Row, Suite 120, San Diego, United States
Iightning
Iightning Nov. 21 at 4:14 AM
1ightning® Options Trade Alert (Actionable) | Buy $GOSS Dec 19 $4 Call | Enter: $0.10 Exit: $0.19 | Profit: 86.38% ROI | https://1ightning.com
0 · Reply
MOOSEN
MOOSEN Nov. 21 at 12:38 AM
$GOSS PONY STROOONG.
0 · Reply
GetRich1nce
GetRich1nce Nov. 21 at 12:30 AM
$GOSS This thing is going doooown 🥱
0 · Reply
mdalinaqvi
mdalinaqvi Nov. 20 at 9:33 PM
$GOSS Rock solid in the carnage, bodes well for next week.
0 · Reply
LeftLane81
LeftLane81 Nov. 20 at 9:23 PM
$GOSS Huge buys at the bell!
0 · Reply
LeftLane81
LeftLane81 Nov. 20 at 5:47 PM
$GOSS Wonder what will happen when they announce Phase 3 PH-ILD start?
1 · Reply
BillyBobBleach
BillyBobBleach Nov. 20 at 4:57 PM
$GOSS all this talk about dips and price targets under $10 is ridiculous. If you’re looking for a big dip now you’ve missed the train; just jump in because this is going above $10 and hitting $15-17 if the 6mwd is over 30
0 · Reply
Escapee
Escapee Nov. 20 at 4:16 PM
$GOSS looking a lil heavy. Maybe dip enough to collect 2% on the calls and grab a few more shares.
0 · Reply
creativeflood
creativeflood Nov. 20 at 2:59 PM
$GOSS hmm, under the radar. Adding for p3.
0 · Reply
Zobzork
Zobzork Nov. 20 at 11:43 AM
$GOSS so... red today, right? Right? My friend is waiting for a dip but itz been green for a while now
0 · Reply
Latest News on GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2025, 5:30 PM EST - 13 days ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Participate in Upcoming Investor Conferences

Nov 7, 2025, 7:31 AM EST - 13 days ago

Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:01 PM EST - 15 days ago

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:41 AM EDT - 2 months ago

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 25, 2025, 7:31 AM EDT - 2 months ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 22, 2025, 7:31 AM EDT - 2 months ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Sep 9, 2025, 9:50 AM EDT - 2 months ago

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 29, 2025, 7:31 AM EDT - 3 months ago

Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 4:01 PM EDT - 3 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Jun 16, 2025, 7:31 AM EDT - 5 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:30 PM EDT - 6 months ago

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 15, 2025, 4:01 PM EDT - 6 months ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 12, 2025, 4:01 PM EDT - 6 months ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

May 7, 2025, 4:01 PM EDT - 7 months ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:01 PM EDT - 9 months ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 13, 2025, 7:42 PM EST - 10 months ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Feb 3, 2025, 7:01 AM EST - 10 months ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 10 months ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Sep 10, 2024, 1:25 AM EDT - 1 year ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:46 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 6, 2024, 7:30 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

May 3, 2024, 8:02 AM EDT - 1 year ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:31 AM EST - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 13, 2023, 4:01 PM EST - 2 years ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Dec 5, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Nov 29, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Oct 3, 2023, 4:08 PM EDT - 2 years ago

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Sep 7, 2023, 7:44 AM EDT - 2 years ago

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Jul 24, 2023, 4:16 PM EDT - 2 years ago

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

Gossamer Bio Announces $212 Million Private Placement Financing

Jul 20, 2023, 7:56 AM EDT - 2 years ago

Gossamer Bio Announces $212 Million Private Placement Financing

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

May 18, 2023, 7:05 AM EDT - 2 years ago

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

May 9, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Apr 2, 2023, 4:12 AM EDT - 2 years ago

Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Mar 17, 2023, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Jan 30, 2023, 4:48 AM EST - 3 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Dec 8, 2022, 1:27 PM EST - 3 years ago

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Dec 6, 2022, 8:19 AM EST - 3 years ago

Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Dec 6, 2022, 7:15 AM EST - 3 years ago

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Iightning
Iightning Nov. 21 at 4:14 AM
1ightning® Options Trade Alert (Actionable) | Buy $GOSS Dec 19 $4 Call | Enter: $0.10 Exit: $0.19 | Profit: 86.38% ROI | https://1ightning.com
0 · Reply
MOOSEN
MOOSEN Nov. 21 at 12:38 AM
$GOSS PONY STROOONG.
0 · Reply
GetRich1nce
GetRich1nce Nov. 21 at 12:30 AM
$GOSS This thing is going doooown 🥱
0 · Reply
mdalinaqvi
mdalinaqvi Nov. 20 at 9:33 PM
$GOSS Rock solid in the carnage, bodes well for next week.
0 · Reply
LeftLane81
LeftLane81 Nov. 20 at 9:23 PM
$GOSS Huge buys at the bell!
0 · Reply
LeftLane81
LeftLane81 Nov. 20 at 5:47 PM
$GOSS Wonder what will happen when they announce Phase 3 PH-ILD start?
1 · Reply
BillyBobBleach
BillyBobBleach Nov. 20 at 4:57 PM
$GOSS all this talk about dips and price targets under $10 is ridiculous. If you’re looking for a big dip now you’ve missed the train; just jump in because this is going above $10 and hitting $15-17 if the 6mwd is over 30
0 · Reply
Escapee
Escapee Nov. 20 at 4:16 PM
$GOSS looking a lil heavy. Maybe dip enough to collect 2% on the calls and grab a few more shares.
0 · Reply
creativeflood
creativeflood Nov. 20 at 2:59 PM
$GOSS hmm, under the radar. Adding for p3.
0 · Reply
Zobzork
Zobzork Nov. 20 at 11:43 AM
$GOSS so... red today, right? Right? My friend is waiting for a dip but itz been green for a while now
0 · Reply
Finnish_boy
Finnish_boy Nov. 20 at 10:21 AM
$GOSS I think SP hits $4 before the readout in early February. Markets dont widely know that the bar is very low (20 meter) considering ph3 baseline. 19 meter is likely enough when stat. sign around 17-18m. 20 meter is already clinically meaningful.
1 · Reply
Tubular9988
Tubular9988 Nov. 20 at 7:16 AM
$GOSS very strong price action. market senses something big from February 2026 phase 3. 200 week SMA stopped September rally to the penny but is now under threat as GOSS looks to break it.
0 · Reply
SadyK189
SadyK189 Nov. 20 at 5:11 AM
Top Stocks to watch tomorrow 2 / 2: $LNAI $GOSS $RDGT $QNRX $SGML LNAI: Looking good on 4hours chart. Key support at 1.05 - 1.17. Next key level to test is 1.75 - 1.90. Currently at 1.39 GOSS is moving slowly and steadily but nicely on daily chart. Key support at 2.40 - 2.60. Next key level to test is 3.6 - 3.85. It may take sometime though. QNRX: Initially alerted last week. Still looking good on daily chart. Key support at 14.60 - 15.30. Next key level to test is 20.70 - 21.50. Currently at 18.18 SGML: Looking good on daily chart. 9.3 - 9.7 is acting as key support zone. Next key level to test is 11.65 - 12.10. Currently at 10.80 RDGT is trending nicely on daily chart. Key support at 3.80 - 4.10. Next key level to test is 5.25 - 5.45. Currently at 4.75
0 · Reply
Iightning
Iightning Nov. 20 at 1:47 AM
1ightning® Options Trade Alert (Actionable) | Buy $GOSS Dec 19 $4 Call | Enter: $0.10 Exit: $0.19 | Profit: 86.38% ROI | https://1ightning.com
0 · Reply
StockScubaDiver
StockScubaDiver Nov. 20 at 1:06 AM
$GOSS holding for a year. Waiting for Feb 2026 Good luck all
0 · Reply
StockBoiChris
StockBoiChris Nov. 19 at 10:18 PM
$GOSS stock is down 84% all time let’s go where 🤔.
3 · Reply
Gila55
Gila55 Nov. 19 at 8:38 PM
$GOSS one down day in past 11 days.
0 · Reply
Gila55
Gila55 Nov. 19 at 8:36 PM
$GOSS stock is up 40% in the last month. Bullish.
0 · Reply
pouncer61
pouncer61 Nov. 19 at 2:40 PM
$GOSS hey...expect further increases in price!
0 · Reply
LeftLane81
LeftLane81 Nov. 19 at 2:39 PM
$GOSS Funny action so far
1 · Reply
boomupwego
boomupwego Nov. 19 at 2:19 PM
$GOSS I used to be very, very wary about pre-market jumps because they typically led to very red days. May very well hold true today but much more confident it’ll be a great, green day.
0 · Reply
Finnish_boy
Finnish_boy Nov. 19 at 10:03 AM
$GOSS H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target. (Nice pop in after hours, i dont read anything from it though)
2 · Reply